アブストラクト
| Title | CKD |
|---|---|
| Subtitle | 特集 心腎連関から新薬まで! 心×腎疾患の薬物治療 心腎連関を考慮した薬物治療 |
| Authors | 風間順一郎 |
| Authors (kana) | |
| Organization | 福島県立医科大学医学部腎臓高血圧内科 |
| Journal | 月刊薬事 |
| Volume | 64 |
| Number | 4 |
| Page | 693-697 |
| Year/Month | 2022 / 3 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | [Points]●心不全の治療薬がCKDに及ぼすメリットとデメリットを考える. ●十分な治療介入を行いつつも, ポリファーマシーを回避するための薬物の取捨選択にも考慮する. ●目標は腎代替療法の絶対回避ではなく, 無理なく安全な腎代替療法に落とし込むことである. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Go AS, et al : Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med, 351 : 1296-1305, 2004
- 2) Tanaka K, et al : Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int, 91 : 227-234, 2017
- 3) Brenner BM, et al : Effects of losartan on renal and cardio-vascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med, 345 : 861-869, 2001
- 4) Lewis EJ, et al : Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. Engl J Med, 345 : 851-860, 2001
- 5) Inomata T, et al : Effects of additive tolvaptan vs. increased furosemide on heart failure with Diuretic resistance and renal impairment-results from the K-STAR Study. Circ J, 82 : 159-167, 2017
残りの9件を表示する
- 6) Mc Causland FR, et al : Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation, 142 : 1236-1245, 2020
- 7) Perkovic V, et al : Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med, 380 : 2295-2306, 2019
- 8) Heerspink HJL, et al : Dapagliflozin in patients with chronic kidney disease. N Engl J Med, 383 : 1436-1446, 2020
- 9) Kato ET, et al : Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation, 139 : 2528-2536, 2019
- 10) Sattar N, et al : Cardiovascular, mortality, and kidney out-comes with GLP-1 receptor agonists in patients with type 2 diabetes : a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol, 9 : 653-662, 2021
- 11) Ito S, et al : Esaxerenone(CS-3150) in patients with type 2 diabetes and microalbuminuria(ESAX-DN) : Phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol, 15 : 1715-1727, 2020
- 12) Heerspink HJL, et al : Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease(SONAR) : a double-blind, randomised, placebo-controlled trial. Lancet, 393 : 1937-1947, 2019
- 13) Nomura K, et al : Renal function in relation to sodium intake : a quantitative review of the literature. Kidey Int, 92 : 67-78, 2017
- 14) Kimura H, et al : Association of polypharmacy with kidney disease progression in adults with CKD. Clin J Am Soc Nephrol, 16 : 1797-1804, 2021
